Table 2.

Univariate and multivariate analyses of clinical parameters for PFS and OS

Variable	No. of patients (%)	PFS			OS
		Median PFS	Univariate analyses (p)	Multivariate analyses, HR (95% CI)	Median OS	Univariate analyses (p)	Multivariate analyses, HR (95% CI)
Age, yr
< 70	209 (69.2)	3.6	0.068		7.5	0.024
≥ 70	93 (30.8)	2.8			5.9		1.345 (1.03–1.757)
Sex
Male	189 (62.6)	3.5	0.482		6.4	0.156
Female	113 (37.4)	3.4			7.6
DM
No	175 (57.9)	3.6	0.858		7.1	0.544
Yes	127 (42.1)	2.8			6.3
Disease statusa,b
Locally advanced	41 (13.6)	4	0.318		11.5	0.047
Metastatic	261 (86.4)	3			6.3		0.994 (0.921–1.073)
Primary cancer
Head	164 (54.3)	3.2	0.371		6.9	0.36
Body	44 (14.6)	3.7			7.7
Tail	71 (23.5)	2.9			6.1
Head and body	2 (0.7)	0.9			2.1
Body and tail	21 (7)	3.4			6.7
Performance
ECOG 0–1	278 (92.1)	3.6	< 0.001		7.4	0.076
ECOG 2–3	24 (7.9)	1		2.018 (1.314–3.101)	2.5
Na, mmol/La
< 135	46 (15.2)	1.8	0.216		2.9	0.001
≥ 135	256 (84.8)	3.6			7.6		0.768 (0.538–1.095)
CA 19-9, U/mLa
< 1,000	183 (60.6)	3.6	0.001		8.9	< 0.001
≥ 1,000	119 (39.4)	2.8		1.326 (1.039–1.694)	5.5		1.373 (1.066–1.768)
Invasive procedures within 30 days
No	239 (79.1)	2.8	0.186		6.0	0.058
Yes	63 (20.9)	3.9			9.2
No. of metastatic lesions
0–2	97 (32.1)	4.1	0.013		10.1	< 0.001
> 2	205 (67.9)	2.7		1.130 (0.875–1.460)	5.7		1.537 (1.179–2.005)

PFS, progression free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus; ECOG, Eastern Cooperative Oncology Group; Na, sodium; CA 19-9, carbohydrate antigen 19-9.

^aAt the start of chemotherapy.

^bIncluded recurred locally advanced/recurred metastatic.